Introduction: Tigecycline has potential utility in the treatment of complex polymicrobial infections or those caused by multi-drug resistant in the ambulatory care setting due to its breath of antimicrobial coverage. Whilst licensed for twice daily intravenous administration, its long half-life permits once daily administration which may facilitate successful outpatient parenteral antibiotic therapy (OPAT). Methods: A retrospective case series of patients receiving once-daily tigecycline under OPAT was analysed at a single centre NHS acute hospital (Jan’16 – Jun’18). Patient demographics, including co-morbidities, antimicrobial indication, concurrent antimicrobial therapies, treatment duration and adverse events related to treatment were recorded using medical records. Treatment outcomes were defined using the British Society of Antimicrobial Chemotherapy National Outcomes Registry (NORS). Results: 25 treatment episodes (24 individual patients) were analysed. The most common indications were bone and joint infections (n=8) and intra-abdominal infections (n=7). Multi-resistant organisms were common, including ESBL-producing Enterobacterales (n=13) and glycopeptide resistant enterococci (n=4). Median treatment duration was 18 days. 19/25 (76%) cases had complete cure of treatment, 3 patients experienced treatment-related adverse reactions necessitating cessation of therapy, and 3 experienced failure due to disease progression. Eight patients experienced non-limiting adverse effects such as nausea, vomiting and rash, and one patient had a transient rise in amylase three-times the upper normal limit (with no evidence of pancreatitis).Conclusion: Once daily tigecycline can be successfully used for management of complex infections in the OPAT setting, with predominantly mild adverse effects, which can be managed with anti-emetics or slow administration.